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Abstract
Introduction: Management of esophageal anastomotic 
leaks (AL) and esophageal perforations (EP) remains difficult 
and often requires an interdisciplinary treatment modality. 
For primary endoscopic management, self-expanding me-
tallic stent (SEMS) placement is often considered first-line 
therapy. Recently, endoscopic vacuum therapy (EVT) has 
emerged as an alternative or adjunct for management of 
these conditions. So far, data for EVT in the upper gastroin-
testinal-tract is restricted to single centre, non-randomized 
trials. No studies on optimal negative pressure application 
during EVT exist. The aim of our study is to describe our cen-
tre’s experience with low negative pressure (LNP) EVT for 
these indications over the past 5-years. Patients and Meth-
ods: Between January 2014 and December 2018, 30 patients 
were endoscopically treated for AL (n = 23) or EP (n = 7). All 
patients were primarily treated with EVT and LNP between 
–20 and –50 mm Hg. Additional endoscopic treatment was 
added when EVT failed. Procedural and peri-procedural 
data, as well as clinical outcomes including morbidity and 
mortality, were analysed. Results: Clinical successful endo-
scopic treatment of EP and AL was achieved in 83.3% (n = 
25/30), with 73.3% success using EVT alone (n = 22/30). Mean 
treatment duration until leak closure was 16.1 days (range 
2–58 days). Additional treatment modalities for complete 
leak resolution was necessary in 10% (n = 3/30), including 
SEMS placement and fibrin glue injection. Mean hospital 
stay for patients with EP was shorter with 33.7 days com-
pared to AL with 54.4 days (p = 0.08). Estimated preoperative 
10-year overall survival (Charlson comorbidity score) was 
39.4% in patients with AL and 59.9% in patients with EP (p = 
0.26). A mean of 5.1 EVT changes (range 1–12) was needed 
in EP and 3.6 changes (range 1–13) in AL to achieve complete 
closure, switch to other treatment modality, or reach endo-
scopic failure (p = 0.38). Conclusion: LNP EVT enables effec-
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tive minimally – invasive endoluminal leak closure from 
anastomotic esophageal leaks and EP in high-morbid pa-
tients. In this study, EVT was combined with other endoscop-
ic treatment options such as SEMS placement or fibrin glue 
injection in order to achieve leak or perforation closure in the 
vast majority of patients (83.3%). Low aspiration pressures 
led to slower but still sufficient clinical results.
© 2020 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Anastomotic esophageal leaks are treated with differ-
ent modalities depending on multiple features, including 
the size and chronicity of leak. Management options are 
early surgical revision (< 72 h after initial operation), en-
doluminal management or, rarely, cervical esophagosto-
my. For perforations of the luminal upper gastrointesti-
nal (GI)-tract, endoscopic measures are often attempted 
initially when mediastinitis is not present and the patient 
is stable.
The chronicity of leakage, size of the leak and the site 
of leakage play a crucial role in initial management deci-
sions. Different endoscopic closure techniques may be 
applied, including the use of through-the-scope clips, 
over-the-scope-clips, self-expanding metal stent (SEMS), 
endoscopic suturing and endoscopic vacuum therapy 
(EVT) [1, 2]. Leakages are reported to occur in 9.5–40% 
after upper GI surgery [3, 4]. Mortality of anastomotic 
leak (AL) following surgery is approximately 10% and 
may decrease to < 10% in experienced high-volume cen-
tres [1, 5]. For > 10 years, EVT has been used with prom-
ising results for anastomotic break-down after colon re-
sections [6]. After these encouraging results, it has since 
been used for leak management in the upper GI tract [7–
9].
Randomized controlled trials comparing endoscopic 
treatment options do not exist in this highly morbid and 
heterogeneous patient cohort. The available data on EVT 
are from single-centre retrospective series, which report 
leakage closure rates by EVT between 70 and 100% [10]. 
The largest cohort is reported by Bludau et al. [11] with 
77 patients. The use of EVT started in Germany, propa-
gated by Wedemeyer and Loske et al. [7, 8, 12, 13]. In the 
beginning, the EVT sponges had to be manually prepared 
and assembled by the treating physician. Recently, how-
ever, only one readymade sponge kit is commercially 
available for use in the upper GI (Esosponge Braun B 
Melsungen, Germany). This product is approved for use 
in esophageal perforations (EP) and ALs only and not for 
pre-emptive EVT.
The aim of this study is to describe the treatment mo-
dalities, clinical success rates and clinical outcomes of pa-
tients undergoing management of AL or EP with low neg-
ative pressure (LNP) vacuum treatment at our centre over 
a 5-year study period.
Patients and Methods
We performed a retrospective analysis of our endoscopic data-
bank (WinData E&L Medical Systems GmbH, Erlangen, Germa-
ny). The study was approved by our institutional review board at 
the University Medical Center Göttingen. The study period was 
January 2014 until December 2018. Patients presenting with post-
operative AL after upper GI surgery, EP and patients receiving pre-
emptive EVT for anastomosis at risk or intraoperative signs of 
ischemia were included. We also included patients who initially 
received surgical revision and developed ALs with the need of EVT 
later on. Patients who initially received successful surgical revision 
were excluded from this study.
Inclusion Criteria
All patients receiving an endoscopic treatment for an AL or EP 
during the study time period were included. Informed consent for 
treatment was obtained by every patient or guardian prior to ther-
apy. Eligible endoscopic treatments included a certified negative 
pressure device for treatment of ALs and perforations, which could 
be manually modified (Eso-Sponge® – Braun B Melsungen, Ger-
many; size 2: external overtube size 19 mm; Fig. 1a–c), over-the-
scope-clips placement (over-the-scope-clip, OVESCO AG, Tübin-
gen, Germany), or Histoacryl fibrin glue (Beriplast P, Combi Set, 
CSL Behring, Marburg, Germany). Patients treated with self-ex-
pending metal stents (SEMS, Full covered stents Mandel + Rupp 
NITI-S Fistel-Stent, Erkrath, Germany) were analysed but exclud-
ed from this study.
Patient demographic data, clinical data regarding the leak, endo-
scopic reports and clinical follow-up data were collected and evalu-
ated. Also, time from surgery to diagnosis was evaluated. Delay be-
tween diagnosis and EVT placement has retrospectively not been 
evaluated as most of the diagnosis was made endoscopically and EVT 
placement was performed right away. In cases where diagnosis was 
performed by imaging studies, EVT placement was performed on the 
same day or < 24 h afterwards. To compare individual morbidity, the 
Charlson comorbidity score was calculated prior to leak develop-
ment, giving a prediction for overall 10-year survival in percentage. 
Clinical success was defined as closure of initial AL or EP and resolu-
tion of purulent secretion by any endoscopic means evaluated during 
endoscopy. Kuehn et al. [10], Möschler et al. [14] and Donatelli et al. 
[15] described different EVT and SEMS placement techniques. The 
EVT placement technique in this study is described below.
EVT was either placed intraluminally or intracavitarily 
(Fig. 2a–d), the latter one represents a technique that was first de-
scribed by Loske et al. [13]. The standard recommended EVT-as-
piration pressure is generally –125 mm Hg [16]. Clinical evidence 
of best applied negative pressure, however, is not available yet. In 
our cohort, we applied negative pressure of –20/–50 mm Hg, in an 
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effort to protect anatomical structures in proximity to the cavity. 
This decision for LNP was taken interdisciplinary with the sur-
geons. We preferred LNP in intrathoracic cavities to avoid local 
tissue damage and our clinical experience showed that LNP was 
sufficient for local debridement.
Statistical analyses and group comparison were performed us-
ing unpaired t tests with Prism 8 statistical software (GraphPad 
Software, San Diego, CA, USA). A p value of < 0.05 was considered 
statistically significant.
cba
Fig. 1. a Eso-Sponge® by Braun B Melsungen; (b) size 2: Eso-Sponge insertion via overtube; (c) intraluminal EVT. 
c d
ba
Fig. 2. a Large AL and dehiscence; (b) simultaneous intraluminal and intracavitary EVT (blue arrow: intralumi-
nal EVT; green arrow: intracavitary EVT); (c) intracavitary EVT (blue arrow: cavity with EVT; green arrow: oe-
sophageal lumen); (d) intermediary results after EVT.
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Peri-Procedural Management during EVT Therapy
Patients treated with EVT received nasogastric/nasojejunal 
tube insertion for direct enteral nutrition, when possible. Other-
wise, total parenteral nutrition was provided for nutritional sup-
port. Additionally, proton pump inhibitors IV (e.g., 40 mg panto-
prazole) were administered during the first 2 weeks in order to 
minimize gastric acid secretion. As soon as leakage or perforation 
was confirmed, an antibiotic and antifungal regimen consisting of 
Vancomycin (1 g intravenous [i.v.] 2 times a day, then dose adap-
tation according to therapeutic serum levels), Meropenem (1 g i.v. 
3×/day) and Caspofungin (initial dose 70 mg, then 50 mg once a 
day i.v.) was administered.
EVT Procedure
EVT can be either applied into a cavity connected to the AL or 
intraluminally (in the case of a free perforation). In general, pre-
pared EVT kits consist of a polyurethane sponge, connected to a 
tube over which negative pressure can be applied via an external 
suction pump (e.g., Medela Thopaz, Medela Medizintechnik, 
GmbH & Co., Handels KG, Germany), similar to drainages in tho-
racic surgery (Fig.  3). First, wound cavities beyond the leak are 
carefully examined endoscopically. In this first step, pus-filled cav-
ities are lavaged carefully and the endoscopist can obtain an over-
view of the local anatomical structures. During the time period of 
this study, the index endoscopy was always performed in the pres-
ence of a general surgeon, and treatment decisions were created in 
multidisciplinary fashion. When deploying the EVT, an overtube 
is placed trans-orally into the cavity or intraluminally. Then the 
Eso-Sponge® was inserted into the oesophagus via the overtube. 
The exact position is finally adjusted under endoscopic view using 
a standard grasper. Before connecting the tube to the external suc-
tion pump, the drainage tube is externalized transnasally and fixed 
to the nose using standard medical tape. Initially, the drain is 
placed like an esophagogastral tube and connected to the rest of 
the sponge device.
Sponge change is repeated every 3–4 days to minimize the risk 
of severe bleeding and sponge adhesion to the oesophagus or the 
wound cavity. Additionally, wound healing or deterioration could 
be controlled this way. During changes, the sponge can be pulled 
out after setting negative pressure to zero. Then, endoscopic re-
application is performed.
In one case with complete anastomotic dehiscence and 2 cavi-
ties, 2 sponges were placed at a time temporarily, each into one of 




In total, 23 patients with postoperative leakages (6 
women, 17 men; mean age women 67.2 years/men 64.5 
years) and 7 patients with EPs (4 women, 3 men; mean 
age women 68.7 years/men 62.3 years) were studied in 
our cohort. All patients were primarily treated with EVT. 
General patient characteristics are displayed in Table 1 
and special patient characteristics per group are displayed 
in Table 2 for AL and in Table 3 for EP. During the study 
period, a total of 272 patients received Ivor Lewis esopha-
gectomies at our surgical department. Of these 272 pa-
tients, 15 patients developed postoperative AL with at-
tempted endoscopic treatment (5.5%).
Clinical success by all endoscopic interventions and 
methods together was 83.3% (n = 25/30). Solo EVT treat-
ment was successful in 73.3% in AL and EP (n = 22/30). 
Leaks requiring a combination of different endoscopic 
devices were present in 3 patients. Here, leak closure was 
ultimately achieved in all patients.
Mean duration of endoscopic treatment leading to 
successful closure of AL and EP (all endoscopic treat-
ments included, n = 25/30) was 18 days (range 2–58 days) 
with a mean number of 4.2 EVT changes per patient 
(range 1–13).
For patients with successful EVT treatment alone in 
AL and EP, the mean duration for closure in all patients 
was 16.1 days.
Subgroup Results: AL versus EP
AL Group
In the AL group (n = 23), overall treatment success was 
87.0% (n = 20/23) and solo EVT treatment success was 
78.3% (n = 18/23). Mean treatment duration for leak clo-
sure was 15.7 days for all treatments and 13.9 days when 
treated only with EVT. Mean hospital stay in AL was 54.4 
days. Two patients were hospitalized for > 120 days in the 
intensive care unit. Diagnosis of AL was made between 
the range of POD 0–30 (mean 8.5 days).
In total, a mean of 3.4 EVT changes (range 1–13×; n = 
18/23) for achieving wound healing were applied. Two 
Fig. 3. Medela Thopaz+ digital chest drainage and monitoring sys-
tem.
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patients received additional endoscopic treatments when 
primary treatment with EVT did not provide definitive 
leak closure (n = 1 oesophageal SEMS placement, n = 1 
fibrin glue injection). The mean estimated 10-year overall 
survival in this patient cohort was 39.4% (Charlson co-
morbidity score).
In n = 18/23 patients (78.2%), oncologic upper GI re-
section was performed after perioperative radio-chemo-
therapy. Prior to EVT, 20% of patients with AL (n = 6/30) 
received surgical revision in between the day of operation 
and POD 12 (mean 4.3 days). All surgically revised pa-
tients showed no healing and were therefore converted to 
EVT treatment. Five patients in AL group received pro-
phylactic EVT during operative or postoperative course, 
where the anastomosis was considered in danger of de-
hiscence. Two out of five patients developed frank leakage 
at the time of therapy and were treated over a longer 
course. Three patients received 1 course of EVT, and 
anastomosis healed normally.
EP Group
Overall treatment success in this group was 71.4% (n = 
5/7 patients). Success of solo primary EVT was 57.1% (n = 
4/7). Mean treatment duration for perforation closure 
was 27 days for all treatments and 25.5 days when treated 
only with EVT. Mean hospital stay was 33.7 days. The 
hospital stay was not significantly different between the 
groups (54.4 AL vs. 33.7 days EP; p = 0.08). A mean of 6.4 
EVT changes (range 1–12×) for perforation closure were 
necessary in this group. Estimated 10-year overall sur-
vival calculated by the Charlson comorbidity score was 
59.9%. No significant difference was found concerning 
morbidity between AL and EP (Al 39.4 vs. EP 59.9%, p = 
0.26).
All patients (n = 7) received primary EVT. In 1 pa-
tient, SEMS placement was necessary to achieve com-
plete wound healing. In 1 patient, palliative EVT was re-
alized for iatrogenic perforation after dilation for stenot-
ic oesophageal cancer. Treatment was stopped after 1 
session of EVT with no treatment effect seen. The pa-
tient was transferred to palliative care ward afterwards. 
In a second patient, no defect closure after Boerhaave 
associated perforation was seen. Here, distal esophageal 
and gastric resection with cervical esophagostomy was 
necessary.
Intracavitary versus Intraluminal Treatment
General technical characteristics are shown in Table 
4. Primary intracavitary EVT was initiated in n = 6/30 
patients (n = 3/23 patients AL and in n = 3/7 patients 
Table 1. General patient characteristics
General patient characteristics Overall patients AL Perforations p value
Indication for EVT, n
Total number of patients 30 23 7
Male 20 17 3
Female 10 6 4
Age, years, mean (SD)
Male 64.5 (11.6) 62.3 (8.1)
Female 67.2 (6.5) 68.7 (6.9)
Charlson Morbidity Score 4.9 (39.4) 3.9 (59.9) 0.26
Cause for surgery, n
Malignancy 23
Adenocarcinoma 17







Diagnosis at day, days 8.50 Immediately
Length of hospital stay, days 54.4 33.7 0.08
Mortality, n (%) 2/30 (6.67) 1 1
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EP) before switching to intraluminal treatment. Intra-
cavitary treatment with LNP showed in this subgroup 
significant cavity size reduction in only 2 out of 6 pa-
tients. In 4 out of 6 patients, intracavitary EVT with 
LNP was insufficient to complete leak closure. There-
fore, additional endoscopic treatment had to be applied 
(2× SEMS). One patient proceeded to esophageal cervi-
costomy and 1 patient died before further endoscopic 
treatment.
Primary intraluminal treatment was initiated in 24 out 
of 30 patients (n = 20/23 patients in AL and n = 4/7 pa-
tients in EP), accordingly. In 4 out of 24 intraluminal 
treatment did not lead to leak closure. Two patients re-
ceived cervical anastomosis, one additional fibrin glue in-
jection before leak closure and 1 patient died during treat-
ment.
Complication, Technique Failure and Mortality
With LNP almost no mucosal erosion patterns after 
EVT were seen. Information of fluid in the Medela suc-
tion container was retrospectively not obtained. Bleeding 
rate after EVT was 7% (n = 2/30), which might also speak 
for few mucosal attachment. Bleeding could be managed 
endoscopically. No major bleeding was documented.
In cases where a feeding tube was placed besides the 
sponge, no adverse events occurred. 
A total of 3 patients received cervical esophagostomy 
after failure of endoscopic therapy (2 AL, 1 EP, EVT du-
ration: 5, 9 and 17 days). Clinical failure was defined as 
continuous purulent secretion, persistence of leak with-
out healing tendency and progression of leak during en-
doscopic treatment.
Table 3. Detailed patient characteristics for EPs















No 63 16 EVT 12 C; later L Yes 1–2 cm
Female Endoscopic
dilation
No 78 33 EVT 2 L Yes 1–2 cm
Female Postoperative 
torquation
No 64 35 EVT 6 L Yes <5 mm
Female Gastroscopy SCC 70 35 EVT + stent 3/1 stent C; later L Radiation Yes >2 cm
Male Boerhaave No 68 35 EVT 3 L No <5 mm
Male Ischemia No 66 32 EVT 9 L Yes >2 cm
Male Endoscopic
dilation
AEG II 53 35 EVT 1 C; later L No >2 cm
EP, esophageal perforation; SCC, squamous cell carcinoma; EVT, Endoscopic Vacuum Therapy.
Table 4. Technical characteristics for AL and EP
  Overall patients Anastomotic insufficency Perforations
Number of EVT changes, mean 4.2 3.4 6.4
First line EVT 30 23 7
Intracavitary EVT 6 3 3
Intraluminal EVT 24 20 4
Additional SEMS 2 1 1
Additional fibrine glue 1 1
Prior surgical revision 6 0
Esophagostomy/esophagectomy 2 (esophagostomy) 1 (esophagectomy + stomy)
AL, anastomotic leaks; EP, esophageal perforations; EVT, endoscopic vacuum therapy; SEMS, self-expanding metal stent.
Jung et al.Digestion8
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Two patients out of 30 died during the immediate clin-
ical follow-up (mortality 6.7% over all groups). Death was 
not directly related to endoscopic treatment but due to 
septic complications, multi-organ failure or progressive 
oncologic disease.
AL Group
In 3 patients, endoscopic treatment failed. In total, 1 
patient died due to reasons not related to endoscopic 
treatment (n = 1: multi-organ failure after mixed cardio-
genic and septic shock). In this patient, leakage closure 
could not be achieved.
EVT was well tolerated by all patients except one who 
externalized his EVT within the first day of EVT treat-
ment. Two patients received cervical esophagostomy as 
endoscopic therapy did not achieve leak closure. 
EP Group
In 2 patients endoscopic treatment failed. In 1 patient, 
progressive ischemic esophageal and gastric necrosis was 
seen, leading to partial esophagectomy and total gastrec-
tomy.
In another patient, advanced esophageal cancer with 
stenosis was present. The patient was transferred to our 
hospital due to iatrogenic perforation after esophageal 
balloon dilation. EVT did not lead to immediate wound 
healing. The patient was transferred to the palliative ward.
Follow-Up
Clinical follow-up data (> 3 months) was available for 
15 out of 30 patients (AL 13/23 patients and EP 2/7 pa-
tients). Mean follow-up time was 11.8 months in AL and 
10 months in EP (range 3–30 months). Reasons for missed 
follow-up were: in house mortality, loss to follow-up or 
recently finished endoscopic treatment < 3 months. Pa-
tients in AL developed anastomotic strictures in 3 cases 
and a colonic-tracheal fistula in 1 case after colon inter-
position. Ten patients remained without stenosis or can-
cer recurrence. In the EP group, 1 patient developed ste-
nosis due to initially non-diagnosed squamous cell carci-
noma. The second patient remained without stenosis. 
Discussion
Within the past few years, EVT has been implemented 
as a treatment option for upper GI-tract luminal defects 
besides SEMS placement [7, 8]. Since then, several case 
series have been published, reporting treatment success 
for EVT in AL and EP in up to 90–100% [10]. Neverthe-
less, there is still a lack of research in this field and sev-
eral clinical questions concerning EVT remain unan-
swered. The biggest study cohort analysed so far was pub-
lished by Laukoetter et al. [17] with 52 patients and the 
cohort of Bludau et al. [11] with 77 patients. Although 
EVT has been showing promising results, its use is not yet 
included in European Society of Gastrointestinal Endos-
copy or other endoscopic guidelines currently.
In our study, overall treatment success was 83.3% for all 
treatment options and success for EVT alone in all cohorts 
was 73.3%. Concerning EVT success, our results are slight-
ly inferior to larger EVT studies by Laukoetter and Hwang 
et al. [17, 18] but similar to Bludau et al. [10, 11] (see also 
Table 5). A possible bias might be the extent of anastomot-
ic insufficiency/leak or in fact less negative pressure. In our 
cohort, at least 2 patients showed complete circular AL 
with additional fistulas, necessitating repetitive EVT [19]. 
Perhaps, these patients would be considered not fit for 
EVT and undergo final esophagostomy in other cohorts. A 
further reason could be delayed diagnosis of AL in the 
studied cohort (mean 8.6 days, range 0–30 days).
Another point of discussion is the use of preformed 
commercially available EVT kits in this study. These high-
ly individual conditions may often require creative and 
individually prepared sponges. In some cases, preformed 
kits were manually adjusted before use in our cohort. Nev-
ertheless, individual sponge adjustment was probably less 
performed in our cohort when compared to other studies.
During the last years, EVT showed better results than 
SEMS placement for leakages and perforations. In Lau-
koetter et al. [17], patients primarily treated with SEMS 
had to be switched more often to EVT to achieve oesoph-
ageal healing. EVT success rate was 93.3% in comparison 
to 63.3% (SEMS) respectively [20]. In a recent meta-anal-
ysis, Rausa et al. [21] showed that EVT in contrast to 
SEMS treatment in oesophageal leaks has a lower major 
complication rate, needs less treatment duration and 
shows lower in house mortality.
Whereas EVT in general is an acknowledged method, 
no human studies or experiences exist so far concerning 
choosing the best applied negative pressure. In general, 
–125 mm Hg negative pressure are applied via KCI (Ki-
netic Concepts Inc., San Antonio, TX, USA) or other 
pumps able generating this negative pressure as recom-
mend by the companies.
In our cohort, negative pressure used, ranged between 
–20 and –50 mm Hg, which is lower than in any other 
study. Nevertheless, all patients treated with –20 mm Hg 
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up to –50 mm Hg negative pressure application showed 
sufficient healing. After LNP EVT in our cohort, we rare-
ly experienced erosion patterns, which are usually pres-
ent in high LNP EVT. It is possible that the way of action 
of LNP is more fluid aspiration (including gastric acid 
fluid and biliary reflux after Ivor-Lewis resection) than 
active wound healing. This may show the importance of 
these fluids impairing wound healing. On the other hand, 
this way of action might explain why LNP is leading to 
slower healing times. Time of EVT application until leak 
closure was not different compared to most of the studies 
[10]. But when compared to the cohort of Bludau et al. 
[11] and also Schorsch et al. [22], treatment with LNP in 
our cohort was longer and led to less treatment success 
(mean 18 days Jung et al. (this study) vs. 11.0 days Bludau 
et al. [11]/Schorsch et al. [22]; mean EVT changes 4.2 
Jung et al. (this study) vs. 2.75 Bludau et al. [11]).
An additional new aspect of our study is the use of the 
Medela (Thopaz) pump for generating moderate negative 
pressure. Normally the Medela pump is used in thoracic 
drains. LNP build-up can be reached slowly using this 
pump. Nevertheless, as leak closure in our cohort took 
more time, slow build up pressure has to be discussed 
whether it is suitable for EVT or not.
An advantage is the monitoring, where an hourly fluid 
quantity is displayed. In case of haemorrhagic fluid secre-
tions, actions can be taken according to displayed infor-
mation. In our experience, the Medela Thopaz drainage 
system was well combined with the Eso-Sponge kit used 
in this study.
It has to be emphasised, that the concept of applying 
–125 mm Hg negative pressure was transferred from ear-
ly skin vacuum therapy studies from Morykwas et al. [23, 
24]. The authors found, that maximum increase of wound 
blood flow was reached at a negative pressure of –125 mm 
Hg leading to improved oxygenation, nutrient delivery to 
the wound bed and faster tissue granulation. Neverthe-
less, these experiments were performed on open skin 
wounds and not on intestinal structures with delicate sur-
rounding tissues such as visceral pleura or vascular struc-
tures. We are convinced that lower pressure secures sur-
rounding tissue and prevents further fistula formation or 
bleeding. In our cohort, patients receiving intracavitary 
placement of EVT, had no reported fistula formation dur-
ing the initial clinical course. Interestingly, fistula forma-
tion has not been described in large EVT cohorts even 
when applying –125 mm Hg negative pressure. In con-
trast to this, bleeding associated with EVT is a known 
complication, reported also by Laukoetter et al. [17].
In total, our clinical experience confirms the suspicion 
that LNP might be also sufficient for local wound de-
bridement and healing. Nevertheless, it cannot be ruled 
Table 5. Comparison of EVT cohorts





for AL, n (%)
Success rate 
















































30 25/30 (83.3) 20/23 (86.96) 5/7 (71.43) 11 (mean 18) 6.67 Yes
EVT, endoscopic vacuum therapy; AL, anastomotic leak; EP, esophageal perforations; SEMS, self-expanding metal stent.
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out that LNP leads to slower wound closure and less treat-
ment success when compared to EVT with –125 mm Hg. 
In our opinion, draining crucial fluids is one part of the 
necessary treatment, but inducing mucosal healing with 
high negative pressure applied to the mucosa might be 
important as well. Probably the latter point is of interest 
for faster and more sufficient mucosal healing when com-
pared to LNP. Future research in this field should eluci-
date this interesting and clinically important question of 
EVT pressure. In our opinion a final statement concern-
ing strength of negative pressure can’t be given yet, due 
to low evidence degree of existing clinical data.
A further important issue in EVT is the positioning of 
the sponge. Intracavitary EVT was first described by Loske 
et al. [13], reporting high closure rates of 100% after a 
mean of 4 EVT changes using –125 mm Hg negative pres-
sure in their cohort of EPs. Interestingly in our cohort, 
intracavitary treatment was not as effective as foreseen. 
Only 2/6 patients showed leak/perforation closure after 
intracavitary EVT and 2 patients needed additive endo-
scopic treatment, 1 patient received esophageal cervicos-
tomy and 1 patient died. On the other hand, we treated 24 
patients intraluminaly with a success rate of 83.3%. LNP 
may had an important role in less efficient healing in in-
tracavitary treatment. Probably, with LNP, the cavities 
were not efficiently closed, therefore fluids could still 
reach the cavity and wound healing was slowed down.
The mortality rate in our study was 6.7% and therefore 
similar to the ones reported in the cohorts of Laukoetter 
et al. [17] (9.6%) and Bludau et al. [11] (12.9%). Interest-
ingly, in 2017 and 2018, no patients died due to ALs in 
our institution and only 3/22 patients (13.6%) were fi-
nally converted to esophagostomy. We have observed a 
learning curve with the EVT, which might play a crucial 
role for the clinical outcome. Hospital stay was signifi-
cantly longer in patients with AL in comparison to EP, 
perhaps due to more severe comorbidities, including on-
cologic disease.
EVT failure was seen in 26.7% (n = 8/30) of all patients 
in our cohort. Reasons for EVT failure were insufficient 
anastomotic perfusion, for which no new granular tissue 
was able to spread. Furthermore sponge positioning, neg-
ative pressure, prior radiochemotherapy, comorbidities 
and the experience of the endoscopic centre with EVT 
might play a crucial role for the outcome. Immediate ad-
verse events due to EVT were rarely seen in our cohort. 
Two out of 30 patients presented minor bleeding directly 
after sponge removal and could be treated endoscopical-
ly. Complications rates were comparable with published 
data [10, 17].
From the endoscopists point of view EVT comes along 
with certain important advantages. First, wound healing 
is observed in a repetitive manner. Second, EVT will ac-
tively aspirate necrotic/purulent tissue, promote wound 
healing and collapse wound cavities. It is the first endo-
scopic tool which allows active local wound debridement 
and healing. Disadvantages are treatment costs [25], re-
peated endoscopies with multiple sedations and difficul-
ties concerning re-nutrition as long as a nasogastric tube 
is not placed at the same time.
Conclusion
LNP EVT shows comparable results to –125 mm Hg 
EVT for upper GI leakages and perforations. Major way 
of action might be aspiration of biliary, gastric and puru-
lent fluids. Intracavitary EVT treatment was not as effi-
cient as intraluminal EVT in our cohort with LNP. Limi-
tations of this study include retrospective nature, relative-
ly small size, single centre design and lack of clinical 
follow-up in all patients.
We recommend that treatment of leakages and perfo-
rations should always be discussed interdisciplinary and 
be adapted according to clinical success and wound heal-
ing or failure. Large, prospective and comparative studies 
are needed to better understand the role of LNP EVT 
compared to other treatment strategies.
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